Related Experiment Videos
Local drug delivery using coated stents: new developments and future perspectives.
Kengo Tanabe1, Evelyn Regar, Chi Hang Lee
1Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Current Pharmaceutical Design
|February 18, 2004
Summary
Drug-eluting stents show promise in preventing restenosis after percutaneous coronary intervention. This review examines various drug candidates and their effectiveness in combating restenosis.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Restenosis remains a significant challenge following percutaneous coronary intervention (PCI).
- Previous attempts using devices and systemic drugs yielded disappointing results.
- Drug-eluting stents (DES) have emerged as a promising therapeutic strategy for restenosis prevention.
Purpose of the Study:
- To review candidate agents for drug-eluting stents.
- To discuss therapeutic objectives for preventing restenosis.
- To summarize the latest information on DES efficacy.
Main Methods:
- Literature review of clinical trials and investigations on drug-eluting stents.
- Analysis of drug mechanisms of action and targets in restenosis.
- Synthesis of data on candidate agents and their effectiveness.
Main Results:
- Sirolimus- and paclitaxel-eluting stents have shown promising clinical data.
- Four potential therapeutic objectives for DES include anti-inflammatory, anti-proliferative, anti-migratory, and pro-endothelial healing.
- Not all drug-eluting stents demonstrate equal effectiveness.
Conclusions:
- Drug-eluting stents are a key focus for preventing restenosis.
- Careful selection of drug agents is crucial for optimal DES performance.
- Ongoing research continues to refine DES technology and drug selection.